+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib



Clinical features of pulmonary arterial hypertension in patients receiving dasatinib



American Journal of Hematology 90(11): 1060-1064



The prognosis of most leukemia patients treated with BCR-ABL tyrosine kinase inhibitors (TKIs) is favorable, and a more precise understanding of serious and potentially irreversible treatment-related toxicities is essential to properly inform treatment choice. Few cases of pulmonary arterial hypertension (PAH) have been reported in patients with leukemia treated with dasatinib, a second-generation BCR-ABL TKI. To better understand characteristics and outcomes of dasatinib-treated patients with PAH, all clinical cases of PAH confirmed by right-heart catheterization in the Bristol-Myers Squibb pharmacovigilance database (Nā€‰=ā€‰41), including 22 previously unpublished cases, were examined for previous treatments for leukemia, patient characteristics, time to PAH onset, and outcomes. Our analysis shows that compared with PAH due to other etiologies, dasatinib-related PAH is atypical, in that it is associated with partial to complete reversibility upon treatment discontinuation. The incidence of dasatinib-related PAH appears to be low. Most PAH cases were observed in patients who had received prior treatments for leukemia. No specific patient attributes appear to be associated with an increased risk of developing PAH while receiving dasatinib. Symptoms of PAH in dasatinib-treated leukemia patients should prompt a thorough workup, including consideration of confirmatory right-heart catheterization. In cases of confirmed PAH, dasatinib should be discontinued.

(PDF emailed within 0-6 h: $19.90)

Accession: 057422795

Download citation: RISBibTeXText

PMID: 26284693

DOI: 10.1002/ajh.24174


Related references

Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17): 2128-2137, 2012

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document. Pulmonary Circulation 7(3): 702-711, 2017

Clinical, functional and hemodynamic features of patients with pulmonary arterial hypertension. Revista Medica de Chile 134(5): 589-595, 2006

Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clinic Proceedings 78(10): 1207-1213, 2003

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulmonary Circulation 7(4): 803-807, 2017

Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension. Annales de Cardiologie et D'angeiologie 61(1): 1-7, 2012

Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. European Respiratory Journal 39(3): 597-603, 2012

Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chinese Medical Journal 121(24): 2497-2503, 2009

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. European Respiratory Journal, 2018

Dasatinib-Induced Pulmonary Arterial Hypertension. British Journal of Clinical Pharmacology, 2018

Comparison of clinical characteristics and survival on patients with idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension during conventional therapy era and targeted therapy era. Zhonghua Xin Xue Guan Bing Za Zhi 42(6): 465-468, 2014

Dasatinib: pulmonary arterial hypertension. French data. Prescrire International 20(120): 241-241, 2011

Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Japanese Journal of Clinical Hematology 57(5): 618-623, 2016

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. European Respiratory Journal 42(3): 869-870, 2014

Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clinical Rheumatology 25(6): 866-872, 2006